CSIMarket Company Name, Ticker, Industry, else..
 
Cogent Biosciences Inc   (NASDAQ: COGT)
 

Cogent Biosciences Inc's Suppliers Performance

COGT's Supply Chain



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

 
COGT Costs vs Sales of Suppliers Growth

• More on COGT Suppliers






Cogent Biosciences Inc's Comment on Supply Chain


The company relies on contract manufacturers to supply the active pharmaceutical ingredient (API) and drug product for its drug candidates, including bezuclastinib. These suppliers operate under purchase orders and comply with current Good Manufacturing Practice (cGMP) regulations. Due to a limited number of manufacturers capable of producing these materials, the company currently obtains the API and drug product for bezuclastinib from single-source suppliers. The company faces risks related to maintaining agreements with third-party manufacturers, regulatory compliance, manufacturing quality, and supply continuity. Loss or failure of these suppliers could materially impact the business, clinical trials, and commercialization efforts. To address these risks, the company plans to establish redundant or second-source supply arrangements.

Cogent Biosciences Inc's Comment on Supply Chain


The company relies on contract manufacturers to supply the active pharmaceutical ingredient (API) and drug product for its drug candidates, including bezuclastinib. These suppliers operate under purchase orders and comply with current Good Manufacturing Practice (cGMP) regulations. Due to a limited number of manufacturers capable of producing these materials, the company currently obtains the API and drug product for bezuclastinib from single-source suppliers. The company faces risks related to maintaining agreements with third-party manufacturers, regulatory compliance, manufacturing quality, and supply continuity. Loss or failure of these suppliers could materially impact the business, clinical trials, and commercialization efforts. To address these risks, the company plans to establish redundant or second-source supply arrangements.







COGT's vs. Suppliers, Data

(Revenue and Income for Trailing 12 Months, in Millions of $, except Employees)



COMPANY NAME MARKET CAP REVENUES INCOME EMPLOYEES
Cogent Biosciences Inc 5,525.19 7.87 -377.18 258
SUBTOTAL 0.00 0.00 0.00 -


Sources: Cogent Biosciences Inc 's official press releases and regulatory filings; CSIMarket.com's supply-chain research; and the financial filings and press releases of other companies cited in this report.
Updated on:
For your research, we’ve provided nine additional tables on Cogent Biosciences Inc ’s suppliers.
You can find them in the navigation menu under Suppliers.
To download the tables, please subscribe.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.